Gluten content of imported gluten-free foods: national and international implications
Authors: Geoffrey M Forbes and Kenneth Dods
Published online: 3 October 2016
Coeliac disease (CD) is the only common disease for which strict dietary compliance is the sole treatment. Sensitivity to gluten varies between patients with CD, so that restricting levels in food to under one part per million (ppm) would protect the maximum number of patients.1 In a daily diet of 500 g food, 1 ppm is equivalent to 0.5 mg, the amount in 1/5000 of a slice of wheat flour bread containing 2.5 g gluten.
International food codes require that foods labelled “gluten-free” (GF) contain less than 20 ppm gluten; in Australia and New Zealand, however, a “no detectable gluten” standard applies.2-4 Current laboratory techniques have a reporting limit of 1 ppm, and a detection limit of 0.5 ppm gluten in food. We assessed the compliance of imported GF-labelled foods with the local food standard, as well as the international capacity of industry to comply with Australian standards, given commercially available analytical reporting and detection limits.
A total of 169 GF-labelled food items manufactured overseas were purchased from four retailers in Perth, Western Australia. The countries of origin were in Europe (nine countries), Asia (nine), and North (two) and South America (five); the food categories included crackers, bread and biscuits (41 items), cereals, flour and grains (37), condiments and sauces (30), spices (21), pasta (16), drinks and soups (15), and confectionary and snacks (nine).
We used a sandwich enzyme-linked immunosorbent assay (ELISA) gliadin detection kit (ESGLISS-48, ELISA Systems). Testing complied with strict food chemistry testing protocols: five variable concentration calibration standards and blank solution tests were used, calibration standards performance was confirmed every 15 samples, internal control materials were employed, and duplicate random samples (1 in 10) from each ELISA plate were tested. All positive results were confirmed on a stored original food sample.
Gluten was detected in 24 of 169 products (14%), of which 20 had unquantifiable but detectable levels (< 1 ppm) and four had quantifiable levels (three, 1.0 ppm; one, 1.1 ppm). Gluten was detected in products supplied from each of the four continents and from each food category (except pasta and drinks/soups).
Our findings, in conjunction with those of 2008 and 2010 surveys of foods mostly produced in Australia,5 have three important implications. Firstly, people with CD can confidently consume GF-labelled products purchased in Australia. Secondly, a marked tightening of international GF standards is readily achievable by industry; the gluten levels in the foods we analysed were all below 1.5 ppm, less than one-tenth of the standard set by the Codex Alimentarius of < 20 ppm.2 Thirdly, we recommend that authorities revise the current Australian GF standard of “no detectable gluten”4 to “≤ 1 ppm”, as it is not practical or reasonable for industry to comply with the stricter standard. In our survey, 14% of products were non-compliant with the current Australian standard, but none contained more than 1.1 ppm gluten.
Competing interests
References
- Office of Food Safety, Center of Food Safety and Applied Nutrition, Food and Drug Administration. Health hazard assessment for gluten exposure in individuals with celiac disease: determination of tolerable daily intake levels and levels of concern for gluten. May 2011. http://www.fda.gov/downloads/Food/FoodScienceResearch/UCM264152.pdf (accessed Apr 2016).
- Food and Agriculture Organization of the United Nations, World Health Organization. Standard for foods for special dietary use for persons intolerant to gluten (Codex Alimentarius Standard 118-1979). Revised 2008. http://www.fao.org/fao-who-codexalimentarius/sh-proxy/en/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252FStandards%252FCODEX%2BSTAN%2B118-1979%252FCXS_118e_2015.pdf (accessed Apr 2016).
- Association of European Coeliac Societies. AOECS standard for gluten-free foods. Brussels: AOECS, 2015. http://www.aoecs.org/downloads/AOECS%20Standard%20November%202015.pdf (accessed Apr 2016).
- Australian Government. Australia New Zealand Food Standards Code. Standard 1.2.8. Nutrition information requirements Federal Register of Legislation, F2015L00395. Mar 2016. http://www.comlaw.gov.au/Details/F2012C00218 F2015L00395 (accessed July 2016).
- NSW Food Authority. Presence of gluten in foods labelled “gluten-free” (NSW/FA/CP047/1101). Mar 2011. http://www.foodauthority.nsw.gov.au/_Documents/scienceandtechnical/gluten_survey_report_2011.pdf (accessed Apr 2016).
Early-Onset Colorectal Cancer With Liver-Only Metastases: A Retrospective Cohort Study Integrating Prospectively Collected Real-World Clinical and Molecular Data From an Australian National Database (2009–2024) to Guide Treatment Planning
Savio G. Barreto, Christos S. Karapetis, Shahid Ullah, Matthew Burge, Susan Caird, Angus Campbell, Azim Jalali, Ross Jennens, Muhammad A. Khattak, Belinda Lee, Stephanie H. Lim, Shehara Mendis, Louise Nott, Timothy J. Price, Jeremy D. Shapiro, Jeanne Tie, Javier Torres, Colin Williams, Rachel Wong, Vanessa Wong, Peter Gibbs
Australian Pathways for Specialist Pain Management and Early Palliative Care for People With Pancreatic Cancer: Developed Using a Community Consensus Approach
Jennifer Philip, Melanie R. Lovell, Kylee Bellingham, Gail Garvey, Gregory B. Crawford, Nicole M. Rankin, Kara Burns, Isabel Young, Vivienne Milch, Dorothy Keefe, Katrina Anderson, James Lawson, Meinir Krishnasamy
Cause‐specific mortality among Queensland people with cirrhosis, by cirrhosis aetiology and decompensation status, 2007–22: a retrospective cohort study
Vikas Bhasker, Jessica R Fong, Paul J Clark, Gunter F Hartel, Richard Skoien, James O’Beirne, Elizabeth E Powell, Patricia C Valery
Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations
Jacob George, Nicole L Allard, Stuart K Roberts, Leon A Adams, Jane Davies, Behzad Hajarizadeh, Jennifer H MacLachlan, Suzanne E Mahady, Rosalie Altus, Catherine Brown, David C Fry, Belinda Greenwood‐Smith, Natali Smud, Patricia C Valery, Nafisa Yussf, Kate Broun, Denise Campbell, Karen Canfell, Chelsea Carle Harrison, Victoria Freeman, Paul Grogan, Catherine Holliday, Suzanne Hughes, Anna Kelly, Cathelijne Kemenade, Claire Latumahina, Amanda McAtamney, Megan Varlow, Joachim Worthington, Susan Yuill, Eleonora Feletto
Assessment of metabolic dysfunction‐associated fatty liver disease in primary care: a consensus statement summary
Leon A Adams, William W Kemp, Kate R Muller, Elizabeth E Powell, Stuart K Roberts, Luis Calzadilla Bertot, Stephanie Best, Gary Deed, Jon D Emery, Samantha L Hocking, Graham R Jones, John S Lubel, Sinead Sheils, Stephen M Twigg, Gerald F Watts, Jacob George
Treatment outcomes for people with hepatitis C referred to tertiary care in Victoria, 2021–22: a retrospective observational study
Elly Layton, Nicole Matthews, Brendan Quinn, Nasra Higgins, Gabrielle Lindeman, Mielle Abbott, Jennifer MacLachlan, Elizabeth Birbilis, Margaret E Hellard, Joseph Doyle, Benjamin C Cowie, Mark Stoové